StreetInsider.com News Articles

Keenova Marks the 2nd Annual National Hand Health Month with New Dupuytren's Contracture Mixed Reality Experience and Awareness Initiatives

Tue, 01 Sep 2026 07:30:00 -0400

Monthlong campaign in September aims to elevate awareness of hand health, encourage early detection of Dupuytren's contracture, and connect patients with appropriate care

DUBLIN, Sept. 1, 2026 /PRNewswire/ -- Keenova Therapeutics plc today announced plans for the 2^nd Annual National Hand Health Month (HHM), a nationwide U.S. observance held each September that is dedicated to raising awareness about hand health and encouraging people to take action when they notice signs of hand conditions.

Keenova Marks the 2nd Annual National Hand Health Month with New Dupuytren's Contracture Mixed Reality Experience and Awareness Initiatives

Tue, 01 Sep 2026 07:30:00 -0400

Monthlong campaign in September aims to elevate awareness of hand health, encourage early detection of Dupuytren's contracture, and connect patients with appropriate care

Keenova doses first patient in Phase 3 hammer toe drug trial

Thu, 20 Aug 2026 07:30:21 -0400

Keenova Therapeutics plc announced that the first patient has been enrolled and dosed in its Phase 3 clinical trial evaluating XIAFLEX® (collagenase clostridium histolyticum) as an investigational nonsurgical treatment for hammer toe.

The trial, designated KN3835-313, is a double-blind, randomized, placebo-controlled study. The primary endpoint assesses whether XIAFLEX reduces flexion contracture of the proximal interphalangeal joint, measuring improvement in the ability to straighten the affected toe. Secondary objectives include changes in foot function, activity limitations, and patient-reported overall severity.

The study is expected to enroll approximately 550 participants across an estimated 35 sites in the United States and is registered on ClinicalTrials.gov

Keenova doses first patient in Phase 3 hammer toe drug trial

Thu, 20 Aug 2026 07:30:21 -0400

The study is expected to enroll approximately 550 participants across an estimated 35 sites in the United States and is registered on ClinicalTrials.gov

Keenova doses first patient in Phase 3 hammer toe drug trial

Thu, 20 Aug 2026 07:30:21 -0400

The study is expected to enroll approximately 550 participants across an estimated 35 sites in the United States and is registered on ClinicalTrials.gov

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Thu, 20 Aug 2026 07:30:00 -0400

First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe
Hammer toe treatment today is limited to mainly orthotics, painkillers, or surgery

DUBLIN, Aug. 20, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that the first patient has been successfully enrolled and received study treatment in its Phase 3 clinical trial evaluating XIAFLEX^® (collagenase clostridium histolyticum) as an investigational nonsurgical treatment for patients with hammer toe.

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Thu, 20 Aug 2026 07:30:00 -0400

First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe
Hammer toe treatment today is limited to mainly orthotics, painkillers, or surgery

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Thu, 20 Aug 2026 07:30:00 -0400

First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe
Hammer toe treatment today is limited to mainly orthotics, painkillers, or surgery

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Thu, 20 Aug 2026 07:30:00 -0400

First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe
Hammer toe treatment today is limited to mainly orthotics, painkillers, or surgery

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Thu, 20 Aug 2026 07:30:00 -0400

First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe
Hammer toe treatment today is limited to mainly orthotics, painkillers, or surgery

Keenova Advances Podiatry Pipeline with First Patient Dosed in Phase 3 Trial of XIAFLEX® (collagenase clostridium histolyticum) for Hammer Toe

Thu, 20 Aug 2026 07:30:00 -0400

First registered, randomized Phase 3 trial evaluating the efficacy, safety, and tolerability of XIAFLEX in adults with hammer toe
No FDA-approved nonsurgical therapies currently indicated for the treatment of hammer toe
Hammer toe treatment today is limited to mainly orthotics, painkillers, or surgery

Keenova Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Strong Performance Driven by Growth in Acthar^® Gel¹ and XIAFLEX^®²

XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study Initiation Expected in Third Quarter 2026

Percocet Divestiture to Complete Exit of Opioid Business

Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year Growth

Conference Call and Webcast Today at 8:00 a.m. ET

Second Quarter 2026 Highlights³

Acthar Gel net sales of $205 million
XIAFLEX net sales of $150 million
Net sales from continuing operations of $517 million
Loss from continuing operations

Keenova Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Strong Performance Driven by Growth in Acthar^® Gel¹ and XIAFLEX^®²

XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study Initiation Expected in Third Quarter 2026

Percocet Divestiture to Complete Exit of Opioid Business

Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year Growth

Conference Call and Webcast Today at 8:00 a.m. ET

Second Quarter 2026 Highlights³

Acthar Gel net sales of $205 million
XIAFLEX net sales of $150 million
Net sales from continuing operations of $517 million
Loss from continuing operations

Keenova Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Strong Performance Driven by Growth in Acthar^® Gel¹ and XIAFLEX^®²

XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study Initiation Expected in Third Quarter 2026

Percocet Divestiture to Complete Exit of Opioid Business

Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year Growth

Conference Call and Webcast Today at 8:00 a.m. ET

Second Quarter 2026 Highlights³

Acthar Gel net sales of $205 million
XIAFLEX net sales of $150 million
Net sales from continuing operations of $517 million
Loss from continuing operations

Keenova Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Strong Performance Driven by Growth in Acthar^® Gel¹ and XIAFLEX^®²

XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study Initiation Expected in Third Quarter 2026

Percocet Divestiture to Complete Exit of Opioid Business

Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year Growth

Conference Call and Webcast Today at 8:00 a.m. ET

Second Quarter 2026 Highlights³

Acthar Gel net sales of $205 million
XIAFLEX net sales of $150 million
Net sales from continuing operations of $517 million
Loss from continuing operations

Keenova Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Strong Performance Driven by Growth in Acthar^® Gel¹ and XIAFLEX^®²

XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study Initiation Expected in Third Quarter 2026

Percocet Divestiture to Complete Exit of Opioid Business

Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year Growth

Conference Call and Webcast Today at 8:00 a.m. ET

Second Quarter 2026 Highlights³

Acthar Gel net sales of $205 million
XIAFLEX net sales of $150 million
Net sales from continuing operations of $517 million
Loss from continuing operations

Keenova Reports Second Quarter 2026 Financial Results

Tue, 11 Aug 2026 06:30:00 -0400

Strong Performance Driven by Growth in Acthar^® Gel¹ and XIAFLEX^®²

XIAFLEX Pipeline Advancing; Positive Phase 3 Plantar Fibromatosis Data Supporting Planned sBLA Submission in Fourth Quarter 2026; Phase 3 Hammer Toe Study Initiation Expected in Third Quarter 2026

Percocet Divestiture to Complete Exit of Opioid Business

Raises Full-Year Acthar Gel Guidance to 20%-22% Year-Over-Year Growth and Tightens XIAFLEX Guidance to High Single-Digits Year-Over-Year Growth

Conference Call and Webcast Today at 8:00 a.m. ET

Second Quarter 2026 Highlights³

Acthar Gel net sales of $205 million
XIAFLEX net sales of $150 million
Net sales from continuing operations of $517 million
Loss from continuing operations

Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology

Mon, 03 Aug 2026 07:30:00 -0400

DUBLIN, Aug. 3, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript examining whether baseline penile pain influences treatment outcomes in men with Peyronie's disease treated with XIAFLEX^® (collagenase clostridium histolyticum). The Keenova‑sponsored posthoc analysis, which evaluated existing XIAFLEX clinical trial data, appears in Translational Andrology and Urology.

Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology

Mon, 03 Aug 2026 07:30:00 -0400

Keenova Therapeutics to Report Second Quarter 2026 Financial Results on August 11, 2026

Thu, 30 Jul 2026 07:00:00 -0400

DUBLIN, July 30, 2026 /PRNewswire/ -- Keenova Therapeutics plc, a leading developer and manufacturer of branded therapeutics, announced today that it will report its second quarter 2026 financial results on Tuesday, August 11, 2026, before market open. The Company will host a conference call on the same day at 8:00 a.m. ET.

Keenova Therapeutics to Report Second Quarter 2026 Financial Results on August 11, 2026

Thu, 30 Jul 2026 07:00:00 -0400

Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research

Mon, 13 Jul 2026 07:30:00 -0400

DUBLIN, July 13, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript about the use of Acthar Gel (repository corticotropin injection) to treat certain severe autoimmune diseases. Sponsored by Keenova, the retrospective, physician-reported, survey-based medical chart review study covered in the manuscript used real‑world clinical data to evaluate patient characteristics, treatment patterns, and physicians' assessments of outcomes among individuals with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis/polymyositis (DM/PM) who received Acthar Gel. The manuscript appears in the peer-reviewed Journal of Comparative Effectiveness Research and is available

Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research

Mon, 13 Jul 2026 07:30:00 -0400

Keenova's Xiaflex meets primary endpoint in plantar fibromatosis trial

Wed, 08 Jul 2026 07:00:33 -0400

Keenova Therapeutics plc announced positive results from its Phase 3 clinical trial of XIAFLEX (collagenase clostridium histolyticum) for the treatment of plantar fibromatosis, a chronic condition that causes collagen nodules to form along the connective tissue supporting the arch of the foot.

The trial, designated EN3835-309, enrolled 436 participants and met its primary endpoint, showing a statistically significant improvement in pain versus placebo as measured by the Average Daily Pain Intensity on the Numeric Rating Scale. The study also met key ranked secondary endpoints related to difficulty and activity limitation as measured by the Foot Function Index scale.

Additional secondary measures, including

Keenova's Xiaflex meets primary endpoint in plantar fibromatosis trial

Wed, 08 Jul 2026 07:00:33 -0400

Additional secondary measures, including